November 04, 2015

Expansion of Research Award Categories Announced

Research on swine respiratory diseases beyond PRRS now eligible for funding

Porcine reproductive and respiratory syndrome (PRRS) continues to challenge the swine industry, both in management and profitability, but it’s not the only respiratory disease attacking producers’ bottom lines. The Respiratory Disease Research Board (formerly the PRRS Research Review Board), with financial support from Boehringer Ingelheim Vetmedica, Inc. (BIVI), is pleased to announce an expansion of the Research Award program to include additional respiratory pathogens.

Beginning in 2016, the Awards for Advancing Research in Respiratory Disease (formerly PRRS Research Awards) will also be open to research projects related to porcine circovirus Type 2 (PCV2), Mycoplasma hyopneumoniae and influenza A virus in swine (IAV-S). This is the first time in the board’s history that projects covering diseases beyond PRRS will be considered.

“We recognize that there are a host of other respiratory disease challenges besides PRRS that impact production and performance,” says Dr. Daryl Olsen, AMVC veterinarian and member of the Respiratory Disease Research Board. “This expansion is exciting because it shows our commitment to meeting the industry’s broad needs for ongoing, applicable swine respiratory disease research.”

Practicing veterinarians and researchers seeking a Research Award need to submit a proposal by January 1, 2016. Additional instructions and submission forms are available at under ‘Download Forms.’ Three $35,000 awards will be available.

Over the last 12 years, Research Awards totaling $1 million supported development of less costly, additional diagnostic testing and sampling processes, identified more effective biosecurity practices, sought to better understand PRRS virus transmission and developed risk assessment tools, therapeutic intervention programs and vaccination strategies. The program is supported through funding from Boehringer Ingelheim Vetmedica, Inc. (BIVI).

“The threat from swine respiratory diseases is always evolving, so ongoing research is necessary to find new and better solutions to problems that reduce production and profitability,” says Dr. Reid Philips, technical manager, BIVI. “When it comes to PRRS and the other diseases now eligible for the Research Awards, experience has proven the value of supporting swine disease science through the Research Award program.”

For more information on the Respiratory Disease Research Board and the Awards for Advancing Research in Respiratory Disease program, visit

About the Respiratory Disease Research Board

The Respiratory Disease Research Board, an independent group of swine veterinarians and researchers, selects the Awards for Advancing Research in Respiratory Disease annually. Board members for the 2016 award selection process include:

  • Luc Dufresne, DVM, Seaboard Foods, Shawnee Mission, Kansas
  • Tim Loula, DVM, Swine Vet Center, P.A., St. Peter, Minnesota
  • Daryl Olsen, DVM, AMVC, Audubon, Iowa
  • Montse Torremorell, DVM, Ph.D., University of Minnesota, St. Paul
  • Bill Mengeling, DVM, Ph.D., Diplo. ACVM, Iowa State University, Ames (Retired)
  • AASV President
  • AASV Young Swine Veterinarian of the Year

About Boehringer Ingelheim Vetmedica, Inc.

Boehringer Ingelheim Vetmedica, Inc. (BIVI) is the fifth-largest animal health company in the United States and produces innovative vaccine and pharmaceutical products for the prevention and treatment of diseases in the swine, cattle, equine and companion animal markets. BIVI is the U.S. subsidiary of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other locations in Ames, Fort Dodge and Sioux Center, Iowa.

With more than 3,600 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about 1.13 billion euros in 2014. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 11 percent of net sales of the Animal Health business in R&D.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.